ICU sedation, delirium & recovery
Clinical features and treatments of VEXAS syndrome in critical care: a scoping review
Authors' conclusion
This review revealed the lack of systematically analyzed studies focusing on VEXAS syndrome in the critical care setting, suggesting a significant gap in understanding the clinical characteristics and optimal treatments for VEXAS syndrome.
Study context
- Population
- Patients with VEXAS syndrome requiring critical care78 reports
- Participants
- 55 patients
- Outcome
- Clinical features and outcomes of critically ill patients with VEXAS syndrome
Methodological detailsPRISMA-ScR guidelines, Joanna Briggs Institute methodology, Cochrane CENTRAL, MEDLINE via PubMed, EMBASE, Web of Science searched May 19, 2024
- PRISMA-ScR guidelines
- Joanna Briggs Institute methodology
- Cochrane CENTRAL, MEDLINE via PubMed, EMBASE, Web of Science searched May 19, 2024
Main finding
As reported in the abstract
Median age (55 cases)
69
Male (of 55 cases)
54 of 55
ICU admission rates
28 to 33%
Mortality rates
18 and 40%
Safety
Infectious complications
- Frequently reported with immunosuppressive and immunomodulatory therapies
Original publication
Clinical features and treatments of VEXAS syndrome in critical care: a scoping review. Crit Care. Published 17 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →